Effect of Metformin on Reducing the Incidence of Cardiovascular Events and Coronary In-Stent Restenosis after Coronary Intervention in Patients with Coronary Heart Disease
FANG Yong, LU Wei, YAN Yu
General Hospital of Wanbei Coal and Electricity Group, Anhui Suzhou 234000, China
Abstract：Objective: To investigate the effect of metformin on the incidence of in-stent restenosis and cardiovascular events in patients with coronary heart disease who underwent coronary intervention. Methods: From February 2020 to February 2022, 50 patients with coronary heart disease who received coronary intervention in Wanbei Coal and Electricity Group General Hospital were selected retrospectively. According to the postoperative treatment methods, they were divided into two groups: metformin group (metformin plus conventional treatment) and conventional treatment group (25 patients in each group). The general information, laboratory indicators, cardiovascular events and in stent restenosis of the two groups were comparatively analyzed. Results: After treatment, the levels of blood glucose, insulin resistance index, low density lipoprotein, total cholesterol, endolipin, tumor necrosis factor-αand hypersensitive C-reactive protein in 2 groups were lower in the model than before treatment (P<0.05), while the levels of omentin-1 in the model were higher than before treatment (P<0.05). The levels of blood glucose, insulin resistance index, low density lipoprotein, total cholesterol, endolipin, tumor necrosis factor-αand hypersensitive C-reactive protein in metformin group were significantly lower than those in conventional treatment group (P<0.05), while the omentin-1 level model was higher than that in conventional treatment group (P<0.05). The incidence of cardiovascular events in metformin group was 8.00% (2/25) lower than that in conventional treatment group 32.00% (8/25) (χ2=4.500, P<0.05). The incidence of coronary restenosis in metformin group was 12.00% (3/25) significantly lower than that in conventional treatment group (36.00% (9/25) (χ2=3.947, P<0.05). Conclusions: The addition of metformin to conventional treatment in patients with coronary heart disease undergoing coronary intervention can further reduce the levels of blood glucose, blood lipid, inflammatory factors and fat factors, and reduce the incidence of coronary stent restenosis and cardiovascular events.
方勇, 芦伟, 闫宇. 冠心病患者行冠状动脉介入术后采用二甲双胍治疗降低心血管事件及冠状动脉支架内再狭窄发生率的影响[J]. 河北医学, 2023, 29(4): 612-616.
FANG Yong, LU Wei, YAN Yu. Effect of Metformin on Reducing the Incidence of Cardiovascular Events and Coronary In-Stent Restenosis after Coronary Intervention in Patients with Coronary Heart Disease. HeBei Med, 2023, 29(4): 612-616.
2023, Vol. 29 
冀公网安备13080202000677号